Aref Al-Kali

Hematologist focused on myeloid diseases. views are mine

[Aref Al-Kali @AlkaliDr]

Comparison of different models in #CCUS
⭐️ models perform differently based on endpoint
⭐️ CCRS/CHRS do well for progression to MN
⭐️ models perform differently to predict MDS vs CMML vs AML
⭐️ to predict OS modified IPSS-m did the best

⁦#ccus https://t.co/CRSwUYknlE

[Aref Al-Kali @AlkaliDr]

Busy poster session with many of @MayoCancerCare staff presenting today. Proud of you 👏 ♥️

@MayoCancerCare #eha2026

@MorieGertz @kimball_md #Kapoor

[Aref Al-Kali @AlkaliDr]

@MayoCancerCare experience in sweet syndrome and #AML by @AntoineNSaliba #eha2026

[Aref Al-Kali @AlkaliDr]

@MayoCancerCare retrospective experience of intensive vs non-intensive Rx in IDHm #AML by @tariqkewan @MHDSheikhNajeeb #eha2026

[Aref Al-Kali @AlkaliDr]

@MayoCancerCare experience in MECOMr #AML by @AntoineNSaliba @emmacstmartinMD #Eha2026

[Aref Al-Kali @AlkaliDr]

@MayoCancerCare experience predicting postHCT survival in pts treated with HMA_VEN by @n_gangat #eha2026

[Aref Al-Kali @AlkaliDr]

@MayoCancerCare new risk model using machine learning in #Vexas. 👏 👏 @a_mangaonkar @tariqkewan #EHA2026. 🔥 🔥

[Aref Al-Kali @AlkaliDr]

@MayoCancerCare experience in prior immune or chemo therapy in zrsr2 MN by @yacout96 #eha2026

[Aref Al-Kali @AlkaliDr]

@MayoCancerCare experience with extramedullary #myeloma by @ZanwarSaurabh #eha2026

[Aref Al-Kali @AlkaliDr]

Mitigating neurotox in #CART by @YiLinMDPhD @MayoCancerCare #eha2026

[Aref Al-Kali @AlkaliDr]

@MayoCancerCare experience in Adaptive hematopoiesis in #TBD. @MrinalPatnaik #eha2026

[Aref Al-Kali @AlkaliDr]

Expert Consensus on #CAD by @MorieGertz @MayoCancerCare #Eha2026

[Aref Al-Kali @AlkaliDr]

@MayoCancerCare experience in outpatient #CART use in lymphoma. @YiLinMDPhD #eha2026

[Aref Al-Kali @AlkaliDr]

#transplant_survivorship by @kimball_md @MayoCancerCare #eha2026

[Aref Al-Kali @AlkaliDr]

@MayoCancerCare experience in sequencing therapy in #myeloma
#eha2026 #Preshant_Kapoor

[Aref Al-Kali @AlkaliDr]

#AJ1_11095 a type II JAk2 inhibitor that shows excellent response in JAKi failure in MF. #eha2026

One of the best drugs presentations until now. 👏 👏

[Aref Al-Kali @AlkaliDr]

#Bezuclastinib in AdvSM is active in decreasing marrow mast cells, tryptase and KIT VAF. #Eha2026

[Aref Al-Kali @AlkaliDr]

#INCA033989 as monotherapy or combo with JAK2i in pts with #CALRm MF. Very encouraging results. #eha2026

[Aref Al-Kali @AlkaliDr]

#LUSP vs PBO as add-on to JAKi in pts with MF requiring blood transfusions. #Eha2026

[Aref Al-Kali @AlkaliDr]

@MayoCancerCare experience using outpatient #melphelan conditioning presented by our fellow Dr #Mathias_Palmer. #EHA2026

[Aref Al-Kali @AlkaliDr]

Good to see you all @mpdrc @Dr_AmerZeidan @tariqkewan . #EHA2026